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Abstract
Background: Various experimental, epidemiological, and clinical studies have shown that hyperuricemia is associated
with development of hypertension, visceral obesity, insulin resistance, dyslipidemia, type 2 diabetes, kidney diseases, and
cardiovascular and cerebrovascular events. Whether hyperuricemia is a cause or effect is a debatable subject. Although
the pathogenesis of these diseases is complex and incompletely understood, it is clear that oxidative stress and damage to
proteins and lipids is common for all of them.
Objective: To determine whether hyperuricemia causes oxidative stress in patients with gout, and to evaluate the effect of
allopurinol treatment on oxidative stress after 1 and 3 months in these patients.
Materials and Methods: Patients with newly diagnosed gout (n = 30) and healthy age- and sex-matched volunteers
(n = 30) were enrolled in the study. They were treated with 100-mg allopurinol 8 hourly in a day for 3 months. Serum uric
acid levels and levels of oxidative stress such as serum malondialdehyde (MDA), erythrocyte catalase (CAT), and
erythrocyte superoxide dismutase (SOD) were measured before treatment, and after 1 and 3 months of treatment.
Pretreatment levels of all the parameters were compared in both the groups using unpaired t-test. The parameters were
also analyzed in test group at 0, 1, and 3 months of treatment using repeated-measures analysis of variance test.
Results: Pretreatment levels of serum uric acid and MDA were signiﬁcantly higher in patients as compared to control group
(P o 0.01). They were signiﬁcantly reduced after 1 (P o 0.05) and 3 months (P o 0.01) of treatment with allopurinol.
Pretreatment levels of CAT and SOD were signiﬁcantly lower in patients as compared to control group (P o 0.01); they
were increased signiﬁcantly after 1 (P o 0.01) and 3 months (P o 0.01) of treatment with allopurinol.
Conclusion: From this study, it can be suggested that hyperuricemia causes oxidative stress in patients with gout. Besides
the main beneﬁt of lowering serum uric acid level, allopurinol also decreases oxidative stress in patients with gout.
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Introduction
Gout is a common crystal-induced arthropathy. It is caused
by a group of heterogenous disorders that lead to either
overproduction or underexcretion of uric acid or both. When
serum uric acid concentration reaches its threshold for
solubility (6.8 mg/dL), it starts to get deposited in the form of
monosodium urate monohydrate crystals in joint spaces and
other tissues. Deposition of these crystals in joint space leads
to neutrophil activation that causes synovial inﬂammation in
short term and joint deformity in long term.[1,2]
Various experimental, epidemiological, and clinical studies
have shown that hyperuricemia is associated and in many
cases predicts development of hypertension, visceral obesity,
insulin resistance, dyslipidemia, type 2 diabetes, kidney
diseases, and cardiovascular and cerebrovascular events.
Whether hyperuricemia is a cause or an effect is a debatable
subject. Although the pathogenesis of these diseases is
complex and incompletely understood, it is clear that oxidative
stress and damage to proteins and lipids is common for all
of them.[3]
Allopurinol is an inhibitor of xanthine oxidase enzyme,
which catalyzes formation of uric acid from xanthine. It is
indicated for treatment of chronic gout and for recurrent attacks
of acute gout.[4] Besides its hypouricemic effect, there are
direct and indirect evidences of antioxidant effect of allopurinol.
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It was shown to scavenge superoxide anion and hydroxyl
radicals in in vitro and experimental studies, whereas it
improves endothelial dysfunction caused by oxidative stress
in patients of congestive heart failure, type 2 diabetes, and
coronary artery disease, and in smokers.[5]
Considering the above-mentioned facts, relationship
among hyperuricemia, allopurinol, and oxidative stress is
complex. There are not enough evidences regarding effect of
hyperuricemia on oxidative stress in humans and antioxidant
effect of allopurinol in patients with gout. Thus, this study was
conducted with the objective to evaluate the effect of
hyperuricemia on oxidative stress in patients with gout.
Another objective was to evaluate whether allopurinol has
any antioxidant effect in these patients.
Materials and Methods
This study was conducted at Government Medical College
and New Civil Hospital, Surat, Gujarat, India, from June 2011
to May 2012. The study protocol was approved by the
institutional ethics committee (MCS/STU/Ethics Approval/
18750/2010).
Subjects
The individuals were divided into two groups: Patient group
and control group.
Patient group: Thirty patients with gout (25 men and 5
women), eligible for allopurinol treatment, were enrolled after
taking informed consent. They were diagnosed by preliminary
criteria for diagnosis of gout given by the American College of
Rheumatology, 1977. Only those patients who were previously
not treated with any hypouricemic drug were enrolled. Mean
age for study group was 42.17 ± 12.54 years.
Control group: Thirty age- and sex-matched healthy
volunteers (25 men and 5 women) were enrolled after taking
informed consent. Mean age for study group was 43.87 ±
12.44 years.
Subjects with a history of cardiovascular diseases, diabetes,
renal diseases; patients with active infections; patients on
medications for diseases other than gout; and smokers and
alcoholics were excluded from the study. Subjects were
instructed not to take any nutritional supplements during the
study period.
Treatment Schedule
The patients with gout were treated by tablet 100-mg
allopurinol three times daily for 3 months. The drug was
procured from Central Medical Store, New Civil Hospital,
Surat, Gujarat, India.
Sample Collection and Biochemical Estimation
Blood samples of control group and that of study group at
the time of enrolment, after 1 month, and after 3 months of
allopurinol treatment were collected. Tests for serum uric acid,
serum malondialdehyde (MDA), erythrocyte superoxide dis-
mutase (SOD), and erythrocyte catalase were conducted.
For oxidative stress parameters, 5 mL venous blood
sample was collected in sodium EDTA (1 mg/mL) tubes and
immediately subjected to biochemical analysis. The blood was
centrifuged at 3000 rpm for 15 min and then plasma separated
was used for serum MDA estimation. The cells were washed
with normal saline three times and RBCs were used for the
estimation of SOD and catalase. RBCs (0.5 mL) were
subjected to lysis by adding 3-mL ice-cold distilled water.
Hemoglobin level in the hemolysate was measured using
automated cell counter and hemoglobinometer machine in the
Department of Pathology, New Civil Hospital, Surat, Gujarat.
Hemoglobin in the hemolysate was precipitated by adding
1 mL ethanol and 0.6 mL chloroform. The mixture was mixed
thoroughly on the vortex and then centrifuged at 3000 rpm for
15 min. Supernatant was used for estimation of erythrocyte
SOD and erythrocyte catalase activity.
Estimation of Serum Malondialdehyde
The thiobarbituric acid reactive substance levels were
estimated per the spectrophotometric method described by
Ohkawa et al.[6] Pink chromogen produced by reaction of
thiobarbituric acid with MDA was measured at 532 nm. The
values are expressed as nM/mL of plasma.
Estimation of Erythrocyte Superoxide Dismutase
The activity of SOD in erythrocytes was determined using
the method described by Marklund and Marklund[7] with some
modiﬁcations as described by Nandi and Chatterjee.[8]
Pyrogallol is autoxidized rapidly in alkaline solution in the
presence of superoxide anion to intermediate products and the
solution ﬁrst becomes yellow-brown with a maximum absor-
bance at 420 nm. The rate of inhibition of pyrogallol
autoxidation brought about by SOD is used for determination
of the enzyme. The values are expressed as U/g of
hemoglobin.
Estimation of Erythrocyte Catalase
Catalase was measured using the method described by
Sinha.[9] Catalase acts on hydrogen peroxide (H2O2) to
release molecular oxygen. When potassium dichromate is
added to this reaction mixture, activity of catalase is destroyed
and any hydrogen peroxide that has not been split by the
catalase reacts with dichromate to give a blue precipitate of
perchromic acid. This unstable precipitate is then decomposed
by heating to give the green solution and its absorbance is
measured at 570 nm. The values are expressed as mmol of
H2O2 consumed/min/mg of hemoglobin.
All chemicals were purchased from ACS Ltd.
Statistical Analysis
All the values are expressed as mean± SD. The levels of
serum uric acid and oxidative stress parameters of control
group and patient group at the time of enrolment was
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compared using unpaired t-test. The comparison of serum uric
acid level and oxidative stress parameters at the time of
enrolment, after 1 month of allopurinol treatment, and after
3 months of allopurinol treatment in patients with gout was
performed using repeated-measures analysis of variance test.
P value o 0.05 was taken as signiﬁcance level. All statistical
analysis was conducted using SPSS software, version 16.0,
for Windows.
Results
Results are shown in Table1. All the values are expressed
as mean± SD. Serum uric acid levels are signiﬁcantly higher
in patient group than in control group at the time of enrolment,
which decreased signiﬁcantly after allopurinol treatment.
A signiﬁcant increase in plasma MDA level whereas a signi-
ﬁcant decrease in SOD and catalase levels were observed in
patient group in comparison to control group at the time of
enrolment, which suggests signiﬁcant increase in oxidative
stress. A signiﬁcant decrease in serum MDA level whereas a
signiﬁcant increase in SOD and catalase levels were observed
in patient group with allopurinol treatment after 1 and 3 months,
which suggests signiﬁcant decrease in oxidative stress after
allopurinol treatment.
Serum Uric Acid Level
The level of serum uric acid in patients with gout was
signiﬁcantly higher than that in control group at the time of
enrolment (P o 0.01). Treatment with allopurinol decreases
serum uric acid level signiﬁcantly after 1 and 3 months
(P o 0.01).
Lipid Peroxidation
The levels of serum MDA, a marker of lipid peroxidation,
were signiﬁcantly higher for the patient group than that for the
control group at the time of enrolment (P o 0.01). In the
patient group, treatment with allopurinol decreased MDA level
signiﬁcantly after 1 (P o 0.05) and 3 months (P o 0.01),
whereas no signiﬁcant difference in MDA level after 1 and
3 months of allopurinol treatment was observed in control group.
Antioxidant Enzymes
SOD and catalase are antioxidant enzymes. Erythrocyte
SOD and erythrocyte catalase levels in study group are
signiﬁcantly lower than those in control group at the time of
enrolment (P o 0.01). Treatment with allopurinol increases
erythrocyte SOD and erythrocyte catalase levels signiﬁcantly
after 1 and 3 months (P o 0.01). No signiﬁcant difference in
SOD level after 1 and 3 months of allopurinol treatment was
observed.
Discussion
Results of this study showed increased oxidative stress in
patients with newly diagnosed gout at the time of enrolment in
comparison to healthy subjects. As other factors known to
cause increase oxidative stress were absent, it may be
suggested that hyperuricemia causes oxidative stress in
patients with gout. The oxidative stress was reduced by
allopurinol treatment (100 mg every 8 hourly) at 1 month and
the effect was same for 3 months of treatment.
Our results are in line with the ﬁndings of oxidative stress
present in various experimental models of hyperuricemia and
antioxidant effect of allopurinol in them.[10,11]
Association of hyperuricemia with hypertension, visceral
obesity, type 2 diabetes, insulin resistance, renal diseases,
and cardiovascular and cerebrovascular events can be
explained on the basis of the results of this study.
As hyperuricemia causes oxidative stress and interrelated trio
of vascular inﬂammation, oxidative stress, and endothelial
dysfunction, which lead to oxidative damage of lipids and
proteins, is the principal cause in pathology of all the above-
mentioned conditions.[3] Further, there are evidences that
cardiovascular mortality and all-cause mortality in these
patients are signiﬁcantly higher than those in patients with
normal serum uric acid levels.[12,13] Allopurinol also improved
endothelial dysfunction in some of the above conditions.
This suggests that association of hyperuricemia with above-
mentioned conditions is not merely a response of body to
increased oxidative stress but hyperuricemia itself causes
oxidative stress and by virtue of this has some role in the
pathology of them. This is also supported by ﬁndings of
LIFE[14] and GREACE[15] trials that showed that beneﬁcial role
Table 1: Serum uric acid, serum malondialdehyde, erythrocyte SOD, and erythrocyte catalase level in control and patient groups
Control group (n = 30) Patient group (n = 30)
At enrolment After 1 month After 3 months
Serum uric acid (mg/dL) 3.8 ± 0.8 6.9 ± 1.6* 5.1 ± 1.3# 5.0 ± 1#
Serum MDA (nM/mL) 2.68 ± 0.69 5.73 ± 1.55* 4.97 ± 0.76## 4.87 ± 0.82#
SOD (U/g of Hb) 1192 ± 149 1059 ± 149* 1155 ± 167# 1165 ± 163#
Catalase (mM of H2O2 consumed/mg/min) 2273 ± 248 1988 ± 149* 2220 ± 163
# 2216 ± 167#
*P o 0.01 in comparison to control group; #P o 0.01 in comparison to study group at enrolment; ##P o 0.05 in comparison to study group at
enrolment.
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of losartan and atorvastatin, respectively, was partly due to
their uric acid–lowering activity in associated cardiovascular
conditions. As scope of this study was limited in terms of time
frame and study population, the effect of hyperuricemia on
cardiovascular parameters and events was not studied, but
presence of oxidative stress in the study population points
toward development of such events in long term as evidenced
by literature.
Under normal physiological conditions, uric acid acts as an
antioxidant in plasma.[16] Our ﬁndings are in contrast to this
concept. This can be explained on the basis of phenomenon
of ‘‘antioxidant–prooxidant urate redox shuttle’’ in which
an antioxidant uric acid acts as prooxidant under certain
conditions, importance of which is when serum uric acid level
lies in upper two thirds of normal range, that is, more than
4 mg/dL and out of range, that is, 6 mg/dL for women and
6.5 mg/dL for men.[17]
The exact mechanism for hyperuriemia-induced oxidative
stress and antioxidant effect of allopurinol was not explored in
this study, but certain hypothesis can be made based on the
earlier works conducted in this ﬁeld. Uric acid by activating
inﬂammatory pathways inducing vascular smooth-muscle-cell
proliferation and increasing low-density lipoprotein cholesterol
oxidation starts the process of atherosclerosis in vascular
walls. In these atherosclerotic plaques, due to combined effect
of ischemia necrosis and apoptosis, there occurs increased
supply of purine nucleic acids and increased activity of xanthine
oxidase enzyme. This results in overproduction of uric acid at
that site and simultaneous production of superoxide anion
that leads to oxidative stress. Increased concentration of uric
acid causes uncoupling of endothelial NO synthase that
further increases superoxide radical production. Owing to
inﬂammation and angiogenesis at atherosclerotic plaques,
there is frequent rupture of vasa vasorum that releases iron
and copper ions in the medium. Superoxide radicals in the
presence of these ions form hydroxyl radicals through Fenton
and Haber–Wiess reactions, which further propagate oxi-
dative damage and increase oxidative stress. Uric acid itself
in these favorable conditions increases ROS production and
lipid peroxidation in human adipocyte through activation of
NADPH oxidase.[17,18]
Allopurinol may decrease oxidative stress by decreasing
serum uric acid and resultant harmful effects as described
earlier. It can also decrease oxidative stress by inhibiting
xanthine oxidase. Xanthine oxidase, besides its function in
purine metabolism, is also involved in superoxide anion
generation.[19] Allopurinol can directly scavenge superoxide
anion and hydroxyl radical, thus decreasing oxidative stress.
Conclusion
From the ﬁndings of this study, it can be suggested that
hyperuricemia, by increasing oxygen free radical production
and resultant oxidative stress, causes tissue damage in
the patients with gout. Allopurinol besides its serum uric
acid–lowering effect provides an additional advantage of
lowering oxidative stress in these patients.
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